CRIS Current Research Information System

FORNARI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.083
EU - Europa 1.638
AS - Asia 780
AF - Africa 78
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 3
Totale 4.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.076
IT - Italia 419
GB - Regno Unito 316
CN - Cina 298
SG - Singapore 260
SE - Svezia 202
DE - Germania 188
IN - India 100
RU - Federazione Russa 85
IE - Irlanda 73
CH - Svizzera 71
FR - Francia 54
VN - Vietnam 54
UA - Ucraina 53
BG - Bulgaria 50
FI - Finlandia 41
EE - Estonia 25
TG - Togo 25
ZA - Sudafrica 23
ID - Indonesia 21
JO - Giordania 17
NL - Olanda 17
CI - Costa d'Avorio 15
EU - Europa 15
BE - Belgio 10
HR - Croazia 9
AT - Austria 8
CA - Canada 6
PK - Pakistan 6
IL - Israele 5
SC - Seychelles 5
DZ - Algeria 4
GR - Grecia 4
HK - Hong Kong 4
CZ - Repubblica Ceca 3
NG - Nigeria 3
A2 - ???statistics.table.value.countryCode.A2??? 2
ES - Italia 2
JP - Giappone 2
KZ - Kazakistan 2
PL - Polonia 2
TH - Thailandia 2
TN - Tunisia 2
BD - Bangladesh 1
BR - Brasile 1
DK - Danimarca 1
EG - Egitto 1
IR - Iran 1
KG - Kirghizistan 1
KR - Corea 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
RO - Romania 1
SI - Slovenia 1
TR - Turchia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 4.599
Salva come PNG Salva come JPEG
Città #
Southend 285
Fairfield 257
Singapore 221
Chandler 184
Ashburn 166
Woodbridge 135
Bologna 127
Seattle 118
Houston 115
Santa Clara 111
Wilmington 109
Ann Arbor 95
Princeton 78
Dublin 73
Bern 68
Cambridge 64
Boardman 60
Sofia 50
Helsinki 38
Dong Ket 35
Jacksonville 30
Nanjing 29
Padova 29
Westminster 27
Lomé 25
Milan 23
San Diego 23
Beijing 21
Jinan 20
Jakarta 19
Berlin 18
Amman 17
Abidjan 15
Los Angeles 15
New York 15
Saint Petersburg 15
Hebei 14
Nanchang 14
Florence 13
Turin 13
Zhengzhou 12
Amsterdam 10
Brussels 10
Pune 10
San Giorgio di Piano 10
Shenyang 10
Guangzhou 9
Mülheim 9
Changsha 8
Falls Church 8
Forlì 8
London 8
Taizhou 8
Verona 8
Bremen 7
Bühl 7
Council Bluffs 7
Des Moines 7
Düsseldorf 7
Jiaxing 7
Nuremberg 7
Redmond 7
Dearborn 6
Shanghai 6
Yubileyny 6
Chengdu 5
Chicago 5
Falkenstein 5
Holon 5
Olalla 5
Phoenix 5
San Lazzaro di Savena 5
Toronto 5
Xi'an 5
Dallas 4
Hyderabad 4
Mahé 4
Medolla 4
Norwalk 4
Philadelphia 4
Shenzhen 4
Tianjin 4
Treviso 4
Vienna 4
Wenzhou 4
Wuhan 4
Abeokuta 3
Bari 3
Boydton 3
Frankfurt Am Main 3
Haikou 3
Hangzhou 3
Lappeenranta 3
Lauterbourg 3
L’Aquila 3
Medford 3
Moscow 3
Munich 3
Ningbo 3
Paris 3
Totale 3.121
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 208
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate 170
LncRNAs as novel players in hepatocellular carcinoma recurrence 152
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 148
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 143
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 141
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 138
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 135
Oncogenic role of miR-483-3p at the IGF2/483 locus. 130
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 127
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 125
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma 124
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 119
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 118
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 117
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 115
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model 114
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 113
Design, Synthesis and Biological Evaluation of Pyrazole derivatives as Potential multikinase Inhibitors in Hepatocarcinoma. 111
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 110
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 108
MicroRNAs in Animal Models of HCC 107
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 106
MicroRNA involvement in hepatocellular carcinoma. 103
TP53/MicroRNA interplay in hepatocellular carcinoma 101
null 101
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 95
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 94
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 94
The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 alpha Activity by Changing miR Expression Patterns in Human Cancer Cells 94
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 88
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 83
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 82
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 77
Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate 70
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 65
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 59
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 57
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 53
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 52
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 49
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 44
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus 42
Animal models of hepatocellular carcinoma prevention 41
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 40
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 39
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC 35
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 32
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic cencerogenesis 30
MicroRNA and hepatocellular carcinoma: biology and prognostic significance 25
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 25
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much s missing? 18
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 15
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 10
Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies 4
Totale 4.796
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.469
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.469
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020293 0 0 0 0 0 0 0 0 126 70 52 45
2020/2021501 92 31 19 16 12 45 34 37 54 39 23 99
2021/2022853 45 20 44 75 60 39 12 120 28 82 215 113
2022/2023936 90 95 56 103 52 78 23 55 164 27 72 121
2023/2024375 40 51 12 47 41 80 8 17 12 27 13 27
2024/2025907 79 211 126 101 159 48 110 36 37 0 0 0
Totale 4.796